COVID-19 y arritmias: relación y riesgo

Driggin, 2020, Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic, J Am Coll Cardiol., 75, 2352, 10.1016/j.jacc.2020.03.031 European Society of Cardiology. ESC Guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. 2020 https://www.escardio.org/static_file/Escardio/Education-General/Topic%20pages/Covid-19/ESC%20Guidance%20Document/ESC-Guidance-COVID-19-Pandemic.pdf Figueroa F, Salas D, Cabrera J, Alvarado CC, Buitrago AF. COVID-19 y enfermedad cardiovascular. Rev Colom Cardiol. 2020, 10.1016.j.rccar.2020.04.004. Guo T, Fon Y, Chen M et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol Mar 27 doi: 10.1001/jama cardio. 2020.1017 Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan China. JAMA. 2020, https://doi.org/10.1001/jama.2020.1585 Lazzerini, 2020, COVID-19, arrhythmic risk and inflammation: mind the gap, Circulation., 10.1161/CIRCULATIONAHA.120.047293 Mehra M, Desai S, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020, https://doi.org/10.1056/NEJMoa2007621. di Giacomo E, Bellelli G, Peschi G, Scarpetta S, Colmegna F1, de Girolamo G, et al. Management of older people during the COVID-19 outbreak: recommendations from a Italian experience. Int J Geriatr Psychiatry. 2020, https://doi.org/10.1002/gps.5318. Baldi E, Sechi GM, Mare C, Canevari F, Brancaglione A, Primi R, et al. Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy. N Engl J Med. 2020, https://doi.org/10.1056/NEJMc2010418. He J, Wu B, Chen Y, Tang J, Liu Q, Zhou S et al. Characteristic electrocardiographic manifestations in patients with COVID-19. Can J Cardiol. 2020, https://doi.org/10.1016/J.cjca.2020.03.028. Saavedra, 2020, Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-Co-2/COVID-19 en establecimientos de atención de la salud, Infectio., 3, 1, 10.22354/in.v24i3.851 Yao X, Ye F, Zhang, Cheng Cui, Baoying Huang, Peihua Niu, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Clin Infect Dis. 2020, https://doi.org/10.1093/cid/ciaa237. Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020, https://doi.org/10.1016/j.cjca.2020.04.003 Sarayani, 2020, Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without choloroquine or hydroxichloroquine, Res Social Adm Pharm., 10.1016/j.sapharm.2020.04.016 Guzik T, Mohiddin S, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020, https://doi.org/10.1093/cvr/cvaa106 van de Brock MPH, Mölmann JE, Abel BGS, Liebregts M, van Dijk VF, van de Garde EMWl. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. 2020, 10.1007s12471-020-01429-7. Silva, 2020, Effect of high vs low doses of chloroquine diphosphate as adjuntive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A randomized clinical trial, JAMA Netw open Saleh M, Gabriels J, Chany D, Soo Kim B, Mansoor A, Mahmood E, et al. The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARSCoV-2 Infection. Cir Arhythm Electrophysiol. 2020, https://doi.org/10.1161/CIRCEP.120.008662 Mercuro, 2020, Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19), JAMA Cardiology, 10.1001/jamacardio.2020.1834 Bessiere, 2020, Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxichloroquine alone or in combination with azithromycin in an intensive care unit, JAMA Cardiol., 10.1001/jamacardio.2020.1787 Mehra, 2020, Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry análisis, Lancet. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949, https://doi.org/10.1016/jantimicag.2020.105949 Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Eng J Med. 2012:3661881-90, https://doi.org/10.1056/NEJMoa1003833 Cao B, Wang D, Wen W, Liu W, Wang J, Fan G, et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Eng J Med. 2020, https://doi.org/10.1056/N EJMoa2001282. Grein J, Ohmagari D, Shing G, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe COVID-19. N. Eng J Med. 2020, https://doi.org/10.1056/NEJMoa2007016 Wang Y, Zhang D, Du G Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomized double-blind, placebo-controlled, multicenter trial. Lancet. 2020, https://doi.org/10.1016/S0140-6736(20)31022-9 Wo Ch, Postema P, Arbelo E, Behr ER, Bezzina CR, Napolitano C, et al. SARS-COV-2, COVID-19 and inherited arrythmia syndromes. Heart Rhythm. 2020 Mar 31, https://doi.org/10.1016/j.hrthm.2020.03.024 Chang D, Saleh M, Garcia-Bengo Y, Choi E, Epstein L, Willner J. COVID-19 infection unmasking Brugada Syndrome. Heart Rhythm Case Rep. 2020, https://doi.org/10.1016/j.hrcr.2020.023.012 Asencio E, Acunzo R, Uribe W, Saad E, Saenz L. Recomendaciones para la medición del intervalo QT durante el uso de medicamentos para el tratamiento de infección por COVID-19. https://www.sociedadsadec.org.ar/wp-content/uploads/2020/04/RECOMENDACIONES-PARA-LA-MEDICION-DEL-INTERVALO-QT-DURANTE-EL-USO-DE-MEDICAMENTOS-PARA-EL-TRATAMIENTO-DE-INFECCION-POR-COVID.pdf.pdf. Cheung C, Davier B, Gibbs K, et al. MultiLead QT screening is necessary for QT measurement: Implications for management of patients in the Covid-19 Era. JACC Clin Electrophys doi:10.1016/j.jacep.2020.04.001 Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, et al. Influence of genotype on the clinical course of the long-QT syndrome International long-QT syndrome registry research group. N Eng J Med. 1998;339:960-5. Tisdale J, Jaynes H, Kingery J, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Cir Cardiovascular Qual Outcomes. 2013;6:479-87, https://doi.org/10.1161/CIRCOUTCOMES.113.000152 Giudecessi, 2020, Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potencial of possible pharmacotherapies for COVID-19, Mayo Clinic Proc., 10.1016/j.mayocp.2020.03.024 Roden, 2020, Considerations for drug Interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment, Circulation., 10.1161/CIRCULATIONAHA.120.047521 Kaye, 2002, Role of magnesium in the emergency department, Emerg Med J., 19, 288, 10.1136/emj.19.4.288 Diness T, Yeh Q, Qi XY, Chartier D, Tsuji Y, Hansen RS, et al. Antiarrhythmic properties of rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome. Cardiovasc Res. 2008;79:61-9, https://doi.org/10.1093/cvr/cvn075 El-Sheif, 2019, Acquired long QT syndrome and electrophysiology of torsade de pointes, Arrhythm Electrophysiol Rev., 2, 122, 10.15420/aer.2019.8.3